Article
A phase II study of gefitinib in patients with metastatic melanoma.
Melanoma research - 1 Aug 2011
Patel Sapna P, Kim Kevin B, Papadopoulos Nicholas E, Hwu Wen-Jen, Hwu Patrick, Prieto Victor G, Bar-Eli Menashe, Zigler Maya, Dobroff Andrey, Bronstein Yulia, Bassett Roland L, Vardeleon Anna G, Bedikian Agop Y
Abstract excerpt
Gefitinib is an inhibitor of the epidermal growth factor receptor, which is frequently expressed on both choroidal and nonchoroidal melanoma cells. We evaluated the clinical efficacy of gefitinib in patients with metastatic melanoma. Patients with stage IV or unresectable stage III melanoma and Zubrod performance status of less than or equal to 2 were eligible. Previous systemic treatment for metastatic disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.